Shire’s Investigator-Initiated Research Grant Program is now accepting submissions for the “Shire Supports Hypoparathyroidism Research” Global Grants Program Designed to Expand Understanding of Hypoparathyroidism, a Rare Endocrine Disorder
Lexington, US – October 16, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG) today announced the extension of its investigator-initiated research grants program for hypoparathyroidism, a rare endocrine disorder. The “Shire Supports Hypoparathyroidism Research” global grants program will be accepting proposals from qualified researchers between September 15 and December 15, 2016. The program is intended to support independent, unsolicited, scientific research requests that advance clinical and scientific research into hypoparathyroidism.
Hypoparathyroidism is a rare condition in which the parathyroid glands do not produce enough parathyroid hormone (PTH). PTH helps control serum calcium, and phosphate levels as well as activation of vitamin D in the body. With too little PTH, blood calcium falls and phosphate rises. Patients can experience a variety of symptoms, including those affecting the neuromuscular system, cognition, as well as, in some cases, seizures and other serious conditions. The most common cause of the condition is surgical removal or radiation damage to the parathyroid glands, although the condition can also be caused by autoimmunity or other underlying genetic disorders.[i],2
“We are proud to support medical and scientific research in rare diseases, and particularly target areas of significant unmet need such as hypoparathyroidism,” said Dr. Philip J. Vickers, Head of Research & Development at Shire. “We welcome proposals from researchers who can help build the scientific community’s knowledge about this condition. Supporting investigator-initiated research is an essential part of our mission to help people living with rare diseases.”
Research Areas of Interest
Beginning September 15, 2016, qualified researchers can submit proposals for research projects that are scientifically legitimate and intended to generate clinically or scientifically meaningful knowledge expanding the understanding of hypoparathyroidism.
Researchers can find more information on evaluation criteria and rules governing the program, and should submit proposals at https://www.shire.com/research-and-development/research-and-educational-grants. Applications will be accepted until December 15, 2016. Grant recipients will be announced in early 2017.
The Shire Supports Hypoparathyroidism Research program is a specific request platform for IIR submissions in the area of hypoparathyroidism. Shire’s existing grants program also remains in place for all other disease areas. Information pertaining to Shire’s standard grants programs can be found at https://www.shire.com/research-and-development/research-and-educational-grants.
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest. www.shire.com
Lexington, US – October 16, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG) today announced the extension of its investigator-initiated research grants program for hypoparathyroidism, a rare endocrine disorder. The “Shire Supports Hypoparathyroidism Research” global grants program will be accepting proposals from qualified researchers between September 15 and December 15, 2016. The program is intended to support independent, unsolicited, scientific research requests that advance clinical and scientific research into hypoparathyroidism.
Hypoparathyroidism is a rare condition in which the parathyroid glands do not produce enough parathyroid hormone (PTH). PTH helps control serum calcium, and phosphate levels as well as activation of vitamin D in the body. With too little PTH, blood calcium falls and phosphate rises. Patients can experience a variety of symptoms, including those affecting the neuromuscular system, cognition, as well as, in some cases, seizures and other serious conditions. The most common cause of the condition is surgical removal or radiation damage to the parathyroid glands, although the condition can also be caused by autoimmunity or other underlying genetic disorders.[i],2
“We are proud to support medical and scientific research in rare diseases, and particularly target areas of significant unmet need such as hypoparathyroidism,” said Dr. Philip J. Vickers, Head of Research & Development at Shire. “We welcome proposals from researchers who can help build the scientific community’s knowledge about this condition. Supporting investigator-initiated research is an essential part of our mission to help people living with rare diseases.”
Research Areas of Interest
Beginning September 15, 2016, qualified researchers can submit proposals for research projects that are scientifically legitimate and intended to generate clinically or scientifically meaningful knowledge expanding the understanding of hypoparathyroidism.
Researchers can find more information on evaluation criteria and rules governing the program, and should submit proposals at https://www.shire.com/research-and-development/research-and-educational-grants. Applications will be accepted until December 15, 2016. Grant recipients will be announced in early 2017.
The Shire Supports Hypoparathyroidism Research program is a specific request platform for IIR submissions in the area of hypoparathyroidism. Shire’s existing grants program also remains in place for all other disease areas. Information pertaining to Shire’s standard grants programs can be found at https://www.shire.com/research-and-development/research-and-educational-grants.
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest. www.shire.com
